砷剂治疗急性早幼粒细胞白血病耐药的初步研究  

THE ELEMENTARY INVESTIGATION ON DRUG RESISTANCE OF ARSENIC TRIOXIDE(As_2O_3) IN TREATMENT OF ACUTE PROMYELOTIC LENKEMIA(APL)

作　　者：王树叶[1] 肖君 杨慧芳[1] 耿洁[1] 李晓霞[1] 王皎[1] 刘澎[1] 胡龙虎[1] 张鹏[1] 

机构地区：[1]哈尔滨医科大学第一临床医学院,150001

出　　处：《白血病》1999年第6期341-342,共2页

摘　　要：目的　探讨Ａｓ２ Ｏ３ 对ＡＰＬ病人的获得性耐药或内在性耐药。方法　８６ 例用Ａｓ２ Ｏ３ 巩固治疗的ＡＰＬ病人在第１次ＣＲ后３ ａ内复发的２３例，２０ 例继续使用Ａｓ２Ｏ３ ，３ 例加用ＨＡ 或ＤＡ 方案。结果　２３ 例复发病人中１５例又获ＣＲ，１例ＰＲ，７ 例ＮＲ，这７ 例中３ 例应用Ａｓ２Ｏ３ ８ 周后改用ＨＡ或ＤＡ而达ＣＲ，４例１ 周内死亡。结论　初治的１３０ 例中７ 例ＮＲ可能存在内在性耐药，复发的２３ 例中也有７ 例表现为耐药性，可能是获得性耐药，而不是多药耐药，所以与ＡＴＲＡ等无交叉耐药，提示Ａｓ２Ｏ３ 的耐药不是单一机制可以解释的。Objective To explore the mechanisms of drug resistance of As 2O 3 in APL treament.Methods 23 relepsed APL patients,who had been treated with As 2O 3 and had achived complete remission (CR),were administered As 2O 3 again.Results Of these 23 cases,15 achived CR again,1 PR,7 NR(of these 7 patients,3 cases were treated with HA or DA scheme and attained CR,the other 4 cases died within 1 week).Conclusion There is required drug resistance,not multidrug resistance in As 2O 3 trentment,so no cross drug resistance is found,and a single mechanism couldn't auount for that.

关 键 词：砷剂 白血病 耐药性 急性 治疗 

分 类 号：R733.710.5[医药卫生—肿瘤]